India Adds 918 COVID-19 Cases in a Single Day as ICMR Issues Revised Guidelines
NEW DELHI: India added 918 fresh coronavirus cases taking the cumulative tally to 4.46 crores, the ministry’s updated data showed on Monday. The active caseload that accounts for 0.01 percent of the total infections rose to 6,350. The weekly positivity rate as per the update was pegged at 0.86 percent while the daily positivity rate stood at 2.08 percent.
The recovery rate stood at 98.8 percent reported 4,41,59,182 recuperations. The death toll rose to 5,30,806 after four fatalities were added two from Rajasthan, one by Karanataka, and one reconciled death by Kerala.
A total of 92.03 crore infected samples have been tested with 45,225 tests done in the last 24 hours. Under the nationwide vaccination srive, 220.65 crore doses of COVID-19 vaccines have been administered. Meanwhile, the ICMR on Sunday issued fresh guidelines for adults in view of the sudden uptick in COVID-19 cases.
“@ICMRDELHI COVID19 National Task Force, @aiims_newdelhi & Dte.GHS revised clinical guidance for management of adult #COVID19 patients. Guideline does not advice use of Lopinavir-ritonavir, HCQ, Ivermectin, Convalescent plasma, Molnupiravir, Favipiravir, Azithromycin, Doxycycline,” Dr Lokesh Sharma, Heath informatics researcher, ICMR tweeted.
“Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of coinfection of COVID-19 with other endemic infections must be considered. Systemic corticosteroids are not indicated in mild disease,” revised guidelines said.
The revised guidelines read –
“Physical distancing, indoor mask use, hand hygiene, Symptomatic management (hydration, anti-pyretics, antitussive) Monitor temperature and oxygen saturation (by applying a SpO probe to fingers) Stay in contact with treating physician.”
“Seek immediate medical attention if difficulty breathing, High-grade fever/ severe cough, particularly if lasting for more than 5 days. A low threshold is to be kept for those with any of the high-risk features.”
In moderate or severe diseases at high risk of progression, the guidelines recommend, “Consider Remdesivir for up to 5 days (200 mg IV on day 1 followed by 100 mg IV OD for the next 4 days)”.